Atezolizumab (Tecentriq®) for adjuvant treatment of NSCLC. HTA ID: 22036

Assessment Status NCPE Assessment Process Complete
HTA ID 22036
Drug Atezolizumab
Brand Tecentriq®
Indication As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC.
Assessment Process
Rapid review commissioned 18/05/2022
Rapid review completed 02/06/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 01/07/2022
Pre-submission consultation with Applicant 04/10/2022
Full submission received from Applicant 02/12/2022
Preliminary review sent to Applicant 05/05/2023
NCPE assessment re-commenced 02/06/2023
Factual accuracy sent to Applicant 06/07/2023
NCPE assessment re-commenced 12/07/2023
NCPE assessment completed 20/07/2023
NCPE assessment outcome The NCPE recommends that atezolizumab (Tecentriq ®) should not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.